| 0.02 0 (0%) | 10-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.1 | 1-year : | 0.15 |
| Resists | First : | 0.08 | Second : | 0.12 |
| Pivot price | 0.05 |
|||
| Supports | First : | 0.01 | Second : | 0.01 |
| MAs | MA(5) : | 0.05 |
MA(20) : | 0.05 |
| MA(100) : | 0.09 |
MA(250) : | 0.49 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 3.7 |
D(3) : | 32.1 |
| RSI | RSI(14): 39.6 | |||
| 52-week | High : | 1.88 | Low : | 0.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BIOL ] has closed above bottom band by 12.9%. Bollinger Bands are 65.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.05 - 0.05 | 0.05 - 0.05 |
| Low: | 0.02 - 0.02 | 0.02 - 0.02 |
| Close: | 0.02 - 0.02 | 0.02 - 0.02 |
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
Mon, 07 Oct 2024
BIOLASE Files for Chapter 11, Pursues Asset Sale to Sonendo - Dentistry Today
Wed, 02 Oct 2024
Biolase stock in flux as company files for bankruptcy - Investing.com
Tue, 01 Oct 2024
BIOLASE files for Chapter 11, plans asset sale to Sonendo - Investing.com
Tue, 01 Oct 2024
BIOLASE Voluntarily Initiates Chapter 11 Proceedings - StockTitan
Tue, 18 Jun 2024
BIOLASE Announces Delisting from Nasdaq - StockTitan
Tue, 18 Jun 2024
BIOLASE Announces Delisting from Nasdaq - AccessWire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 37 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 6.5 (%) |
| Shares Short | 1,670 (K) |
| Shares Short P.Month | 593 (K) |
| EPS | 16.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.13 |
| Profit Margin | -41.7 % |
| Operating Margin | -27.9 % |
| Return on Assets (ttm) | -28 % |
| Return on Equity (ttm) | -736.3 % |
| Qtrly Rev. Growth | -19.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.25 |
| EBITDA (p.s.) | -0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | 0 |
| PEG Ratio | -0.1 |
| Price to Book value | -0.16 |
| Price to Sales | 0.01 |
| Price to Cash Flow | -0.07 |
| Dividend | 115.19 |
| Forward Dividend | 0 |
| Dividend Yield | 575950% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|